-
22 December 2020: OIA response: funding for blood glucose monitors via Named Patient Pharmaceutical Assessment
-
21 December 2020: OIA response: average age of initiation of statin therapy in New Zealand
-
21 December 2020: OIA response: cannabidiol with tetrahydrocannabinol (Sativex) clinical advice paper for PTAC
-
11 December 2020: OIA response: Special authority data for temozolomide for the treatment of neuroendocrine tumours
-
4 December 2020: OIA response: organisations who responded to proposal to fund two new medicines for type 2 diabetes
-
3 December 2020: OIA response: funding data for rare disorders medicines
-
3 December 2020: OIA response: FreeStyle Libre flash glucose monitor and Dexcom continuous glucose monitor, Tandem insulin pump
-
2 December 2020: OIA response: anti-vascular endothelial growth factor (“anti-VEGF”) agents
-
27 November 2020: OIA response: special authority approvals for adalimumab, etanercept, secukinumab,
-
25 November 2020: OIA response: Special authority funding data for insulin pump consumables
-
24 November 2020: OIA response: funding for blood glucose monitors and test strips
-
19 November 2020: OIA response: decision to change the tetanus vaccine and immunisation schedule
-
18 November 2020: OIA response: cost of funding oral vinorelbine
-
18 November 2020: OIA response: information relating to funding continuous glucose monitors (CGMs)
-
16 November 2020: OIA response: public funding of Trikafta
-
16 November 2020: OIA response: consultation submissions for proposal to modify PHARMAC’s approach t
-
16 November 2020: OIA response: fingolimod use and annual expenditure (2017-2020)
-
05 November 2020: OIA response: ustekinumab NPPA applications for Crohn’s disease and/or ulcerative
-
2 November 2020: OIA response: Hydroxychloroquine in the treatment of COVID-19
-
28 October 2020: OIA response: Special Authority approval data for olaparib, rituximab
-
20 October 2020: OIA response: Special Authority data for somatropin and pegylated interferon alfa-2
-
16 October 2020: OIA response: Canterbury DHB distribution/dispensing data for influenza vaccine, an
-
15 October 2020: OIA response: Information related to PHARMAC employee remuneration/salary bands
-
14 October 2020: OIA response: Dispensing data for siltuximab, tocilizumab and bedaquiline
-
12 October 2020: OIA response: Decision process for funding criteria for teriparatide (Forteo)
-
11 October 2019: OIA response: Cancer drugs data
-
2 October 2020: OIA response: Multiple scerosis (MS) patient numbers
-
1 October 2020: OIA response: Funding data for ustekinumab via the Exceptional Circumstances Framewo
-
1 October 2020: OIA response: Special Authority funding data for lenalidomide (Revlimid)
-
20 November 2020: OIA response: implications of switching from pharmaceuticals to medicinal cannabis
-
30 September 2020: OIA response: Funding data for Hylo-Fresh eye drops
-
29 September 2020: OIA response: Information regarding Named Patient Pharmaceutical Assessment (NPPA
-
28 September 2020: OIA response: Application data for multiple sclerosis treatments
-
24 September 2020: OIA response: Cost-benefit analysis for ustekinumab
-
24 September 2020: OIA response: Patient numbers and cost utility analysis for ivacaftor (Kalydeco)
-
18 September 2020: OIA response: Funding plans for progesterone only oral contraceptive pill (POP) d
-
3 September 2020: OIA response: Erectile dysfunction medications available and funded in New Zealand
-
3 September 2020: OIA response: Cost of funding tramadol in 2019
-
28 August 2020: OIA response: Droperidol supply data
-
28 August 2020: OIA response: Data for funded intravenous iron usage
-
28 August 2020: OIA response: Data for HIV antiretroviral usage
-
17 August 2020: OIA response: Information regarding subsidised prescriptions for goserelin and leupr
-
13 August 2020: OIA response: Special Authority data for pembrolizumab and nivolumab for June 2020
-
10 August 2020: OIA response: Information regarding PTAC subcommittee minutes
-
5 August 2020: OIA Response: Information regarding Spinraza funding
-
30 July 2020: OIA response: Dispensing NPPA B medicines
-
29 July 2020: OIA response: Information related to the prescription and/or use of generic medicines
-
28 July 2020: OIA response: annual funding volumes of trastuzumab
-
28 July 2020: OIA response: indemnities sought from pharmaceutical companies for out-of-stock/supply issues
-
27 July 2020: OIA response: funding and purchase data for lenalidomide and bortezomib
-
20 July 2020: OIA response: medicines funded for the treatment of multiple sclerosis
-
20 July 2020: OIA response: annual funding of food thickeners Aptamil and Nutilis
-
20 July 2020: OIA response: hospital purchasing data and Special Authority approvals for azacitidine
-
16 July 2020: OIA response: Special Authority approvals for methylphenidate for treatment of ADHD vs narcolepsy
-
16 July 2020: OIA response: Hydroxychloroquine for the treatment or prevention of COVID-19
-
16 July 2020: OIA response: Anaesthetic gases
-
16 July 2020: OIA response: Special Authority data for Risperdal Consta, Zyprexa Relprevv, Invega Sustenna
-
15 July 2020: OIA response: payments to the New Zealand Drug Foundation
-
13 July 2020: OIA response: Special Authority and funding data for anti-epileptic medicines
-
9 July 2020: OIA response: Special Authority approval data for enoxaparin sodium
-
3 July 2020: OIA response: Special Authority data for ADHD medicines
-
3 July 2020: OIA response: Ministerial briefings – medicines supply and funding decisions
-
3 July 2020: OIA response: ministerial briefings
-
25 June 2020: OIA response: NPPA applications and exceptional circumstances applications for lamotri
-
19 June 2020: OIA response: Discontinuation of phenelzine sulphate
-
19 June 2020: OIA response: Pembrolizumab and nivolumab
-
19 June 2020: OIA response: Ritalin
-
18 June 2020: OIA response: Nationwide Special Authority data by immunology indication
-
11 June 2020: OIA response: Official complaints
-
25 May 2020: OIA response: Cost increases caused by COVID-19
-
18 May 2020: OIA response: Funding applications declined
-
23 April 2020: OIA response - Consumer Advisory Committee (CAC)
-
20 April 2020: OIA response: Widely dispensed medicines
-
16 April 2020: OIA response - Fentanyl
-
7 April 2020: OIA response - PTAC’s record of consideration for hypothyroidism Nov 2018
-
3 April 2020: OIA response - Levothyroxine supply
-
31 March 2020: OIA response: Vinorelbine
-
31 March 2020: OIA response: Effect of COVID-19 on medicine supply
-
18 March 2020: OIA response - Supply of funded medicine
-
17 March 2020: OIA Response: Medicines from China
-
17 March 2020: OIA response: Anti-epileptic medicines
-
17 March 2020: OIA response: PrEP Data
-
16 March 2020: OIA response: Preparations for COVID-19
-
13 March 2020: OIA response: Security of supply of medicines
-
12 March 2020: OIA response: Supply of cladribine and dacarbazine
-
9 March 2020: OIA response: New Zealand Pharmaceutical Market
-
28 February 2020: OIA response: Utrogestan SA
-
27 February 2020: OIA response: Anti-rejection medications for transplant patients
-
24 February 2020: OIA response: Lamotrigine brand change
-
24 February 2020: OIA response: Cilazapril with hydrochlorothiazide
-
24 February 2020: OIA response - Ibrutinib
-
20 February 2020: OIA response - PHARMAC's budget
-
11 February 2020: OIA response: Lamotrigine exceptional circumstances applications
-
4 February 2020: OIA response: Hospital purchases of special foods
-
3 February 2020: OIA response: Tafamidis and amyloidosis
-
31 January 2020: OIA response: Mirena statistical information
-
30 January 2020: OIA response: Zapril
-
14 January 2020: OIA response: Asthma inhaler devices dispensed